PACIRA BIOSCIENCES, INC. Debt Securities, Available-for-sale, Amortized Cost
PACIRA BIOSCIENCES, INC. (PCRX) had Debt Securities, Available-for-sale, Amortized Cost of $45.19 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $45.19M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $57.92M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $79.85M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $98.73M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $45.19M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $57.92M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $79.85M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $98.73M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $145.40M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $209.98M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $207.69M 10-K · filed 2026-02-26 |
| 2024-09-30 | $207.40M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $157.32M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $141.92M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $127.63M 10-K · filed 2025-02-27 |
| 2023-09-30 | $136.38M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $134.47M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $147.20M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $222.51M 10-K · filed 2024-02-29 |
| 2022-09-30 | $238.01M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $195.43M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $226.41M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $70.65M 10-Q · filed 2022-11-03 |
| 2021-09-30 | $559.72M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $540.69M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $558.22M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $516.85M 10-Q · filed 2021-11-03 |
| 2020-09-30 | $450.10M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $255.01M 10-Q · filed 2020-08-06 |
| 2019-12-31 | $278.20M 10-K · filed 2021-03-01 |
| 2017-12-31 | $317.72M 10-K · filed 2018-02-28 |
| 2017-03-31 | $274.81M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $136.68M 10-K · filed 2018-02-28 |
| 2016-09-30 | $136.71M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $137.22M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $128.41M 10-Q · filed 2016-05-02 |
| 2015-12-31 | $115.50M 10-K · filed 2017-03-01 |
| 2015-09-30 | $133.87M 10-Q · filed 2015-10-27 |
| 2015-06-30 | $138.39M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $133.96M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $143.65M 10-K · filed 2016-02-25 |
| 2014-09-30 | $156.49M 10-Q · filed 2014-10-30 |
| 2014-06-30 | $69.17M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $45.81M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $59.63M 10-K · filed 2015-02-24 |
| 2013-09-30 | $78.45M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $87.32M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $83.93M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $30.90M 10-K · filed 2014-02-25 |
| 2012-09-30 | $58.18M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $62.74M 10-Q · filed 2012-08-09 |
| 2011-12-31 | $29.97M 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |